456-05-3

Usage

Uses

Used in Research Applications:
α-(Aminomethyl)-4-fluorobenzyl alcohol is used as a research chemical for studying its effects on the central nervous system and its potential as a psychotherapeutic medication. It aids in understanding the mechanisms of action and the therapeutic potential of similar compounds.
Used in Pharmaceutical Development:
In the pharmaceutical industry, α-(Aminomethyl)-4-fluorobenzyl alcohol is used as a starting material or intermediate in the development of new medications targeting the central nervous system. Its study contributes to the advancement of psychopharmacology and the discovery of safer and more effective treatments for various conditions.
Used in Toxicological Studies:
α-(Aminomethyl)-4-fluorobenzyl alcohol is utilized in toxicological research to evaluate its neurotoxicity and potential adverse effects on the cardiovascular system. This research is crucial for understanding the risks associated with its use and for developing strategies to mitigate these effects.
Used in Regulatory Frameworks:
Due to its psychoactive properties and potential for abuse, α-(Aminomethyl)-4-fluorobenzyl alcohol is involved in the development and enforcement of regulatory frameworks in many jurisdictions. Its study helps inform policies and guidelines for the safe and controlled use of such substances.

Upstream product

• 17628-74-9 p-fluorophenylglyoxalmonoxime 
• 133721-87-6 2-(4-fluorophenyl)-2-hydroxyacetonitrile 
• 459-57-4 4-fluorobenzaldehyde 
• 18511-62-1 4-fluorostyrene oxide 
• 403-29-2 2-bromo-4'-fluoroacetophenone 
• 1017172-13-2 2-[2-(4-fluoro-phenyl)-2-hydroxy-ethyl]-isoindole-1,3-dione 
• 82585-50-0 2-[2-(4-fluoro-phenyl)-2-oxo-ethyl]-isoindole-1,3-dione 
• 369-43-7 2-amino-1-(4-fluorophenyl)ethan-1-one 
• 1029598-42-2 1-(4-fluorophenyl)-2-nitroethanol 
• 456-00-8 2-amino-4'-fluoroacetophenone hydrochloride 
• 864539-93-5 tert-butyl [2-(4-fluorophenyl)-2-hydroxyethyl]carbamate 
• 75-52-5 nitromethane 
• 118888-01-0 rac-2-azido-1-(4-fluorophenyl)ethanol 
• 118887-70-0 2-azido-1-(4-fluoro-phenyl)-ethanone 

Downstream Products

• 2967-77-3 5-(4-fluoro-phenyl)-4,5-dihydro-oxazol-2-ylamine 
• 1232828-36-2 1-(4-fluoro-phenyl)-2-[4-(pyrazin-2-yloxy)-benzylamino]-ethanol 
• 1239713-08-6 N-[2-(4-fluorophenyl)-2-hydroxyethyl]benzo[b]furan-2-carboxamide 
• 1426152-48-8 C₁₅H₁₃FN₄O₂S 
• 1426152-52-4 C₁₅H₁₁FN₄O₂S 
• 19338-43-3 5-(4-fluorophenyl)-1,3-oxazolidin-2-one 
• 1299491-14-7 (R)-N-[2-hydroxy-2-(4-fluorophenyl)ethyl]benzamide 
• 1268050-33-4 N-[2-hydroxy-2-(4-fluorophenyl)ethyl]benzamide 
• 951626-54-3 6-(4-fluorophenyl)morpholin-3-one 
• 62243-70-3 2-(4-fluorophenyl)-morpholine 
• 1414772-52-3 2-{[3-(1-benzofuran-2-yl)imidazo[1,2-b]pyridazin-6-yl]amino}-1-(4-fluoro-phenyl)ethanol 
• 875305-44-5 [rac]-(4-tert-butyl-benzyl)-[2-(4-fluoro-phenyl)-2-hydroxy-ethyl]-amine 

Relevant academic research and scientific papers

DOPAMINE D3 RECEPTOR ANTAGONISTS HAVING A MORPHOLINE MOIETY

The disclosure provides compounds of formula (I) or pharmaceutically acceptable salts thereof: The disclosure also provides processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them, and their use

Novel morpholine scaffolds as selective dopamine (DA) D3 receptor antagonists

A new series of morpholine derivatives has been identified as selective DA D3 receptor antagonists; their in vitro profile and pharmacokinetic data are provided.

Efficient preparation of biologically important 1,2-amino alcohols

An efficient three-step methodology developed for the preparation of 1,2-amino alcohols. In the first step a rapid coupling between bromoketones and potassium phthalimide in ionic liquid produced-phthalimido ketones in quantitative yields, which is followed by a facile reduction using NaCNBH 3 in acetic acid to give corresponding phthalimido alcohols and finally effecting hydrazinolysis in water at 60C to yield biologically important 1,2-amino alcohols.

One-pot combination of enzyme and Pd nanoparticle catalysis for the synthesis of enantiomerically pure 1,2-amino alcohols

One-pot combinations of sequential catalytic reactions can offer practical and ecological advantages over classical multi-step synthesis schemes. In this context, the integration of enzymatic and chemo-catalytic transformations holds particular potential for efficient and selective reaction sequences that would not be possible using either method alone. Here, we report the one-pot combination of alcohol dehydrogenase-catalysed asymmetric reduction of 2-azido ketones and Pd nanoparticle-catalysed hydrogenation of the resulting azido alcohols, which gives access to both enantiomers of aromatic 1,2-amino alcohols in high yields and excellent optical purity (ee >99%). Furthermore, we demonstrate the incorporation of an upstream azidolysis and a downstream acylation step into the one-pot system, thus establishing a highly integrated synthesis of the antiviral natural product (S)-tembamide in 73% yield (ee >99%) over 4 steps. Avoiding the purification and isolation of intermediates in this synthetic sequence leads to an unprecedentedly low ecological footprint, as quantified by the E-factor and solvent demand.

Exploiting an allosteric binding site of PRMT3 yields potent and selective inhibitors

Protein arginine methyltransferases (PRMTs) play an important role in diverse biological processes. Among the nine known human PRMTs, PRMT3 has been implicated in ribosomal biosynthesis via asymmetric dimethylation of the 40S ribosomal protein S2 and in c

Regio-selective synthesis of 1,2-aminoalcohols from epoxides and chlorohydrins

A simple and efficient procedure for the regio-selective synthesis of 1,2-aminoalcohols from terminal epoxides and chlorohydrins by using NaHMDS as the source of amine is reported. The wider scope and utility of this method is demonstrated.

Novel amide- and sulfonamide-based aromatic ethanolamines: Effects of various substituents on the inhibition of acid and neutral ceramidases

In the present study we describe the design and synthesis of a series of amide- and sulfonamide-based compounds as inhibitor of recombinant acid and neutral ceramidases. Inhibition of ceramidases has been shown to induce apoptosis and to increase the efficacy of conventional chemotherapy in several cancer models. B-13, lead in vitro inhibitor of acid ceramidase has been recently shown to be virtually inactive towards lysosomal acid ceramidase in living cells at lower concentrations and for a shorter time of treatment, suggesting the development of more potent inhibitors. In this study, a detailed SAR investigation has been performed to understand the effect of different substituents on the phenyl ring of amide- and sulfonamide-based compounds that partially resemble the structure of well-known inhibitors such as B-13, D-e-MAPP as well as NOE. Our results suggest that the electronic effects of the substituents on phenyl ring in B-13 and D-e-MAPP analogues have negligible effects either in enhancing the inhibition potencies or for selectivity towards aCDase over nCDase. However, the hydrophobicity and the steric effects of longer alkyl chains (n-Pr, n-Bu or t-Bu groups) at the phenyl ring were found to be important for an enhanced selectivity towards aCDase over nCDase.

ARYL-HYDROXYETHYLAMINO-PYRIMIDINES AND TRIAZINES AS MODULATORS OF FATTY ACID AMIDE HYDROLASE

Certain aryl-hydroxyethylamino-pyrimidine and triazine compounds are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, energy metabolism disorders, and movement disorders (e.g., multiple sclerosis). Methods of synthesizing such compounds are also disclosed.

Indole, indazole and indoline derivatives as CETP inhibitors

The present invention relates to compounds of formula (I): wherein —X—Y—, R1 to R11 and n are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prevention of diseases which are mediated by CETP inhibitors.

SUBSTITUTED MORPHOLINE AND THIOMORPHOLINE DERIVATIVES

The present invention relates to morpholine and thiomorpholine derivatives of the general formula I or pharmaceutically acceptable salts thereof and their use.